Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 13/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129978 | 1.00 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTPKMKDM4E | |
| SCHEMBL29788558 | 0.88 | HPGD (0.73) | ALDH1A1LMNAMAPTPKMKDM4E | |
| SCHEMBL443596 | 0.88 | HPGD (0.73) | ALDH1A1LMNAMAPTPKMKDM4E | |
| SCHEMBL18036523 | 0.86 | MAPT (0.75) | ALDH1A1LMNAMAPTPKMKDM4E | |
| SCHEMBL27518071 | 0.86 | HPGD (0.74) | ALDH1A1LMNAMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL4140342 | 0.83 | MAPT (0.67) | ALDH1A1LMNAMAPTPKMKDM4E | |
| SCHEMBL1527190 | 0.83 | SIRT6 (0.67) | ALDH1A1LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL30900326 | 0.83 | SIRT6 (0.67) | ALDH1A1LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL2711990 | 0.83 | MAPT (0.77) | ALDH1A1LMNAMAPTPKMKDM4E | |
| SCHEMBL5445416 | 0.82 | MAPT (0.65) | ALDH1A1LMNAMAPTPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158872-A1 | 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2275413-B1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| CN-101921236-B | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG | 2013-01-16 | — | — | CN | disclosed |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1135124-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| CN-1296485-A | Substituted indolealkanoic acids | INST FOR PHARM DISCOVERY INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| CN-1265591-A | Coumpound | ZENECA LTD (GB) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000032180-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | ALDH1A1 338/4885LMNA 3538/4885MAPT 4218/4885 |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | ALDH1A1 513/4885LMNA 4301/4885MAPT 4550/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | ALDH1A1 338/4885LMNA 3538/4885MAPT 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.